Esperion Therapeutics Stock Price and Value Analysis

Should you buy Esperion Therapeutics stock? (NasdaqGM:ESPR). Let's see how it does in our automated value investing analysis system.

ESPR Free Cash Flow Trend

Free Cash Flow trendline for ESPR
Free Cash Flow trendline for Esperion Therapeutics

Hmm, we can't give any reliable projection for Esperion Therapeutics's growth rate. The company either has too few years of historical data for us to examine, or it's in the habit of losing money.

None of this means it's a bad stock. Maybe it's new and growing quickly, or maybe it's turning things around. We can't say anything sensible about it, so we won't say it's obviously undervalued right now. Proceed at your own risk!

  • This company has stable growth.
  • This stock looks overpriced.
  • This company is less known than others.
  • This company is not making money.
  • This company pays no dividend.

Inside the ESPR Numbers

ESPR Price
(Esperion Therapeutics stock price per share)
PE Ratio versus Sector 100% lower than other Healthcare stocks
PE Ratio versus Industry 100% lower than other Biotechnology stocks
Free Cash Flow Jitter 17%

Is Esperion Therapeutics Stock on Sale?

Based on our analysis, we believe that you should not buy Esperion Therapeutics right now. It might be a good stock to own—we just can't prove it with value analysis right now. Proceed with caution.

Should You Buy ESPR Stock?

Does Esperion Therapeutics have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.